参考文献

1.Lehman CD，Lee CI，Loving VA，et al.Accuracy and value of breast ultrasound for primary imaging evaluation of symptomatic women 30-39 years of age.AJR Am J Roentgenol，2012，199（5）：1169-1177.

2.Feig S.Cost-effectiveness of mammography，MRI，and ultrasonography for breast cancer screening.Radiol Clin North Am，2010，48（5）：879-891.

3.Evans A，Whelehan P，Thomson K，et al.Differentiating benign from malignant solid breast masses：value of shear wave elastography according to lesion stiffness combined with greyscale ultrasound according to BI-RADS classification.Br J Cancer，2012，107（2）：224-229 .

4.Barr RG.Sonographic breast elastography：a primer.J Ultrasound Med，2012，31（5）：773-783.

5.Gruber R，Jaromi S，Rudas M，et al.Histologic work-up of non-palpable breast lesions classified as probably benign at initial mammography and/or ultrasound（BI-RADS category 3）.Eur J Radiol，2013，82（3）：398-403.

6.Masroor I，Afzal S，Sufian SN.Imaging guided breast interventions.J Coll Physicians Surg Pak，2016，26（6）：521-526.

7.Skaane P，Bandos AI，Gullien R，et al.Comparison of digital mammography alone and digital mammography plus tomosynthesis in a population-based screening program.Radiology，2013，267（1）：47-56.

8.Pauwels EK，Foray N，Bourguignon MH.Breast cancer induced by X-ray mammography screening? A review based on recent understanding of low-dose radiobiology.Med Princ Pract，2016，25（2）：101-109.

9.Hardesty LA.Issues to consider before implementing digital breast tomosynthesis into a breast imaging practice.AJR Am J Roentgenol，2015，204（3）：681-684.

10.Hayes MM.Adenomyoepithelioma of the breast：a review stressing its propensity for malignant transformation.J Clin Pathol，2011，64（6）：477-484.

11.顾雅佳.数字乳腺X线摄影应用研究进展.中国癌症杂志，2013，23（8）：609-612.

12.徐依耑，李文华，陈亚青.超声联合X线摄影对小于2cm乳腺肿块的诊断价值.临床超声医学杂志，2015，17（2）：98-101.

13.Ramamurthy S，D’Orsi CJ，Sechopoulos I.X-ray scatter correction method for dedicated breast computed tomography：improvements and initial patient testing.Phys Med Biol，2016，61（3）：1116-1135 .

14.Bickelhaupt S，Laun FB，Tesdorff J，et al.Fast and noninvasive characterization of suspicious lesions detected at breast cancer X-ray screening：capability of diffusion-weighted MR imaging with MIPs.Radiology，2016，278（3）：689-697.

15.Deng B，Fradkin M，Rouet JM，et al.Characterizing breast lesions through robust multimodal data fusion using independent diffuse optical and X-ray breast imaging.J Biomed Opt，2015，20（8）：80502.

16.张嫣，王颀，郭庆禄，等.病理性乳头溢液的MRI评估.中华临床医师杂志（电子版），2013，7（9）：3777-3781.

17.张嫣，余浩杰，王颀，等.乳腺叶状肿瘤的MRI表现与病理特征分析.实用医学杂志，2013，29（14）：2328-2330.

18.尤超，顾雅佳，彭卫军，等.MRI鉴别乳腺导管原位癌与其他导管内病变的价值.中国癌症杂志，2014，24（6）：463-468.

19.张嫣，汪登斌，陈园园，等.129例乳腺导管内乳头状瘤的MRI表现分析.放射学实践，2015，30（11）：1072-1075.

20.Iakovou IP，Giannoula E.Nuclear medicine in diagnosis of breast cancer.Hell J Nucl Med，2014，17（3）：221-227.

21.Evangelista L，Cervino AR.Nuclear imaging and early breast cancer detection.Curr Radiopharm，2014，7（1）：29-35.

22.Nakajo M，Kajiya Y，Kaneko T，et al.FDG PET/CT and diffusion-weighted imaging for breast cancer：prognostic value of maximum standardized uptake values and apparent diffusion coefficient values of the primary lesion.Eur J Nucl Med Mol Imaging，2010，37（11）：2011-2020.

23.Groheux D，Giacchetti S，Moretti JL，et al.Correlation of high 18F-FDG uptake to clinical，pathological and biological prognostic factors in breast cancer.Eur J Nucl Med Mol Imaging，2011，38（3）：426-435.

24.Yang HL，Liu T，Wang XM，et al.Diagnosis of bone metastases：a meta-analysis comparing 18FDG PET，CT，MRI and bone scintigraphy.Eur Radiol，2011，21（12）：2604-2617.

25.Cooper KL，Harnan S，Meng Y，et al.Positron emission tomography（PET）for assessment of axillary lymph node status in early breast cancer：a systematic review and metaanalysis.Eur J Surg Oncol，2011，37（3）：187-198.

26.Grassetto G，Fornasiero A，Otello D，et al.18F-FDG-PET/CT in patients with breast cancer and rising Ca 15-3 with negative conventional imaging：a multicentre study.Eur J Radiol，2011，80（3）：828-833.

27.Bernsdorf M，Berthelsen AK，Wielenga VT，et al.Preoperative PET/CT in early-stage breast cancer.Ann Oncol，2012，23（9）：2277-2282.

28.Teke F，Teke M，Inal A，et al.Significance of hormone receptor status in comparison of 18F-FDG-PET/CT and 99Tcm-MDP bonescintigraphy for evaluating bone metastases in patients with breast cancer：single center experience.Asian Pac J Cancer Prev，2015，16（1）：387-391.

29.曾贤伍，董峰，杨碎胜，等.99Tcm-MIBI显像诊断乳腺癌及腋窝淋巴结转移的临床价值.甘肃医药，2012，31（11）：801-805.

30.Garami Z，Hascsi Z，Varga J，et al.The value of 18F-FDG PET/CT in early -stage breast cancer compared to traditional diagnostic modalities with an emphasis on changes in disease stage designation and treatment plan.Eur J Surg Oncol，2012，38（1）：31-37.

31.Park JS，Lee AY，Jung KP，et al.Diagnostic performance of breast-specific gamma imaging（BSGI）for breast cancer：Usefulness of dual-phase imaging with 99Tcm-sestamibi.Nucl Med Mol Imaging，2013，47（1）：18-26.

32.李蕾，张秀丽，霍宗伟，等.99Tcm-硫胶体不同制备条件及注射部位对乳腺癌前哨淋巴结检出的影像.中华核医学与分子影像杂志，2014，34（4）：296-308.

33.Yoneyama H，Tsushima H，Onoguchi M，et al.Optimization of attenuation and scatter corrections in sentinel lymph node scintigraphy using SPECT/CT systems.Ann Nucl Med，2015，29（3）：248-255.

34.Kong AL，Tereffe W，Hunt KK，et al.Impact of internal mammary lymph node drainage identified by preoperative lymphoscintigraphy on outcomes in patients with stage I toⅢ breast cancer.Cancer，2012，118（24）：6287-6296.

35.杨余朋，郑刚，郑美珠，等.乳腺癌前哨淋巴结解剖学定位及其临床意义的研究.中华肿瘤防治杂志，2010，17（14）：1100-1103.

36.Pahk K，Rhee S，Cho J，et al.The role of interim 18F-FDG PET/CT in predicting early response to neoadjuvant chemotherapy in breast cancer.Anticancer Res，2014，34（8）：4447-4455.

37.Crippa F，Agresti R，Sandri M，et al.18F-FLT PET/CT as an imaging tool for early prediction of pathological response in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy：a pilot study.Eur J Nucl Med Mol Imaging，2015，42（6）：818-830.

38.Kim BS.Usefulness of breast-specific gamma imaging as an adjunct modality in breast cancer patients with densebreast：a comparative study with MRI.Ann Nucl Med，2012，26（2）：131-137.

39.Keto JL，Kirstein L，Sanchez DP，et al.MRI versus breastspecific gamma imaging（BSGI）in newly diagnosed ductal cell carcinoma-in-situ：a prospective head-to-head trial.Ann Surg Oncol，2012，19（1）：249-252.

40.Rhodes DJ，Hruska CB，Phillips SW，et al.Dedicated dualhead gamma imaging for breast cancer screening in women with mammographically dense breasts.Radiology，2011，258（1）：106-118.

41.Kim BS，Moon BI，Cha ES.A comparative study of breastspecific gamma imaging with the conventional imaging modality in breast cancer patients with dense breasts.Ann Nucl Med，2012，26（10）：823-829.

42.Svahn TM，Chakraborty DP，Ikeda D，et al.Breast tomosynthesis and digital mammography：a comparison of diagnostic accuracy.Br J Radiol，2012，85（1019）：e1074-1082.

43.Michell MJ，Iqbal A，Wasan RK，et al.A comparison of the accuracy of film-screen mammography，full-field digital mammography，and digital breast tomosynthesis.Clin Radiol，2012，67（10）：976-981.

44.Gennaro G，Hendrick RE，Ruppel P，et al.Performance comparison of single-view digital breast tomosynthesis plus single-view digital mammography with two-view digital mammography.Eur Radiol，2013，23（3）：664-672.

45.Noroozian M，Hadjiiski L，Rahnama-Moghadam S，et al.Digital breast tomosynthesis is comparable to mammographic spot views for mass characterization.Radiology，2012，262（1）：61-68.

46.Ling CM，Coffey CM，Rapelyea JA，et al.Breast-specific gamma imaging in the detection of atypical ductal hyperplasia and lobular neoplasia.Acad Radiol，2012，19（6）：661-666.

47.Hruska CB，Weinmann AL，Tello Skjerseth CM，et al.Proof of concept for low-dose molecular breast imaging with a dual-head CZT gamma camera.Part Ⅱ.Evaluation in patients.Med Phys，2012，39（6）：3476-3483.

48.Berg WA，Blume JD，Adams AM，et al.Reasons women at elevated risk of breast cancer refuse breast MR imaging screening：ACRIN 6666.Radiology，2010，254（1）：79-87.

49.Conners AL，Hruska CB，Tortorelli CL，et al.Lexicon for standardized interpretation of gamma camera molecular breast imaging：observer agreement and diagnostic accuracy.Eur J Nucl Med Mol Imaging，2012，39（6）：971-982.